| Nov 11 |
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
|
| Nov 8 |
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?
|
| Nov 6 |
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario
|
| Nov 5 |
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
|
| Oct 31 |
Anavex gains as lead asset slows Alzheimer’s disease progression by a third
|
| Oct 31 |
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
|
| Oct 17 |
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
|
| Oct 9 |
Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
|
| Oct 8 |
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
|
| Sep 20 |
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
|
